Orforglipron vs Petrelintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3502970, OWL833
Orforglipron is Eli Lilly's oral, once-daily GLP-1 receptor agonist, and the headline is that it is a small molecule, not a peptide, so it survives the gut and can be taken as a plain pill with no food or water restrictions. It is being developed for type 2 diabetes and obesity and has completed multiple successful Phase 3 trials. As of mid-2026 it is filed for regulatory review but not yet approved.
Also: ZP8396
Petrelintide is a long-acting amylin analog from Zealand Pharma, co-developed with Roche, designed as a once-weekly injection for obesity. The pitch is gentler weight loss than GLP-1 drugs but with far less nausea and vomiting. Two phase 2 trials read out positively in 2026 (up to 10.7% weight loss at 42 weeks), and a roughly 7,000-person phase 3 program has started. It is not approved anywhere.
Key Comparison Insights
- Orforglipron is FDA approved, while Petrelintide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Orforglipron has stronger research evidence (FDA Approved) compared to Petrelintide (Human Trials).
Detailed Comparison
| Attribute | Orforglipron | Petrelintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Orforglipron activates the same GLP-1 receptor that injectable drugs like semaglutide target, which curbs appetite, slows stomach emptying, and triggers insulin release when blood sugar is high. The difference is chemistry. Semaglutide is a fragile peptide that the digestive tract chews up, which is why it normally needs an injection or a specially formulated pill taken on an empty stomach. Orforglipron is a non-peptide small molecule engineered to bind the same receptor while being stable enough to swallow like any other tablet. Same biological lever, far more convenient delivery. | Amylin is a hormone your pancreas releases alongside insulin after meals. It acts on the brainstem to make you feel full sooner, slows stomach emptying, and curbs glucagon after eating. Zealand says amylin signaling also helps restore sensitivity to leptin, the body's long-term fullness signal. Native amylin is unusable as a drug because it clumps into fibrils and lasts minutes, so petrelintide was engineered to stay stable at neutral pH, avoid fibril formation, and last a week. That stability also means it can be co-formulated with other peptides, which is why Roche plans to combine it with its own GLP-1/GIP drug. The theory is that amylin gives more of a natural fullness feeling than GLP-1 drugs do, with fewer GI side effects; the tolerability part looks real so far, the bigger-picture claims still need phase 3. |
| Common Dosing | Limited community data available See research protocols | Not publicly disclosed (once-weekly trial doses) Once weekly |
| Administration | Oral tablet daily | Subcutaneous injection once weekly |
| Typical Duration | Long-term use expected | 16 weeks (phase 1b) to 42 weeks (phase 2) in completed trials |
| Best Time to Take | Any time of day, same time daily | Same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The evidence base here is strong and recent, anchored by large Phase 3 programs. In the obesity ATTAIN-1 trial (72 weeks), all three doses beat placebo for weight loss, and full results were published in the New England Journal of Medicine. ATTAIN-2, in adults with obesity and type 2 diabetes, was published in The Lancet and showed clinically meaningful weight loss plus improvements in waist circumference, blood pressure, non-HDL cholesterol, and triglycerides. On the diabetes side, ACHIEVE-1 was the first Phase 3 win for any oral small-molecule GLP-1 drug, and in the head-to-head ACHIEVE-3 trial orforglipron beat oral semaglutide on both A1C and weight. Side effects mirror the rest of the GLP-1 class: mostly nausea, vomiting, and diarrhea, generally mild to moderate. The realistic read is that this is a genuine breakthrough in delivery rather than a brand-new mechanism, and approval decisions are expected to follow the completed filings. | A 16-week phase 1b trial (48 people) reported up to 8.6% mean weight loss at the highest dose versus 1.7% on placebo, with no early plateau. The phase 2 ZUPREME-1 trial (493 people with obesity or overweight, mean BMI 37) reported in March 2026 up to 10.7% mean weight loss at 42 weeks versus 1.7% on placebo. That is clearly less than semaglutide or tirzepatide produce, but tolerability stood out: no vomiting at the maximally effective dose, and side-effect dropouts (4.8%) no higher than placebo (4.9%). ZUPREME-2 (220 people with obesity and type 2 diabetes) reported in October 2026: 7.4-9.2% weight loss at 28 weeks versus 2.0% on placebo, placebo-adjusted HbA1c drops of 0.61-0.88 points, and GI dropouts of 1.9% versus 1.7%. Roche and Zealand have started phase 3a (ZUPREME-3, -4 and -5, about 7,000 people in total, including a cardiovascular-disease population). Honest take: a well-tolerated, moderate-strength drug whose real value may be as a combination partner, and the full peer-reviewed phase 2 data are still pending. |
Frequently Asked Questions: Orforglipron vs Petrelintide
What is the difference between Orforglipron and Petrelintide?
Orforglipron is a weight loss peptide that orforglipron is eli lilly's oral, once-daily glp-1 receptor agonist, and the headline is that it is a small molecule, not a peptide, so it survives the gut and can be taken as a plain pill with no food or water restrictions. it is being developed for type 2 diabetes and obesity and has completed multiple successful phase 3 trials. as of mid-2026 it is filed for regulatory review but not yet approved. Petrelintide is a weight loss peptide that petrelintide is a long-acting amylin analog from zealand pharma, co-developed with roche, designed as a once-weekly injection for obesity. the pitch is gentler weight loss than glp-1 drugs but with far less nausea and vomiting. two phase 2 trials read out positively in 2026 (up to 10.7% weight loss at 42 weeks), and a roughly 7,000-person phase 3 program has started. it is not approved anywhere. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Orforglipron or Petrelintide?
Neither is universally "better" - the choice depends on your specific goals. Orforglipron is typically used for weight loss purposes, while Petrelintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Orforglipron and Petrelintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Orforglipron and Petrelintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.